- 期刊
- OpenAccess
Mitomycin-C對血管增生性青光眼之效果
Effect of Topical Mitomycin-C in Neovascular Glaucoma
摘要
Mitomycin-C併小樑切除術近幾年來已被廣泛的使用在各類青光眼的治療。為了評估其使用在血管增生性青光眼的效果及安全性，我們收集了12個血管增生性青光眼的病患共13隻眼，施以小樑切除術並輔以0.4 mg/cc的Mitomycin-C局部敷用，術前有10眼接受全視網膜光凝固治療(PRP)，二眼行全視網膜冷凍治療(PRC)，1眼無任何治療。追蹤6個月到30個月，其中10眼(77%)眼壓在術後可控制在21mmHg以下（包括2眼需要使用降眼壓藥物）。術後併發症中早期最常見的有前房出血10眼，前房過淺2眼及前房有滲出物5眼。晚期併發症中，眼壓無法控制有3眼，白內障加重有8眼，其中3眼到了完全白化的程度。根據本研究的結果，Mitomycin-C併小樑切除術使用於血管增生性青光眼是有效及安全的。
關鍵字
無資料並列摘要
Topical use of mitomycin-c intraoperatively at the filtration site improved the surgical result of filtering operation. To evaluate the efficacy and safety of this procedure in patients with neovascular glaucoma, we collected 13 eyes of 12 patients, in whom a 0.4 mg/ml solution of mitomycin-c was applied between tenon's capsule and the sclera, beneath partial thickness scleral flap, both for 5 minutes during trabeculectomy. Most patients had PRP or PRC before trabeculectomy. The follow-up period ranged from 6 to 38 months. Ten eyes (77%) had an intraocular pressure of less than 21 mmHg with or without topical antiglaucoma medication (2 with antiglaucoma medication). Three eyes (23%) failed with maximal antiglaucoma medications. No significant ocular toxicity from mitomycin-c was observed within this study. Post-op vision was reduced in six eyes due to cataract, progression of underlying disease, or uncontrolled introacular pressure. The instances of hyphema, shallow anterior chamber, and hypotony were higher than usual. These results suggest that intraoperative application of mitomycin-c is effective in neovascular glaucoma.